<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271024</url>
  </required_header>
  <id_info>
    <org_study_id>13976A (R01 DA016834)</org_study_id>
    <secondary_id>R01DA016834</secondary_id>
    <nct_id>NCT00271024</nct_id>
  </id_info>
  <brief_title>Efficacy of Naltrexone in Women's Smoking Cessation</brief_title>
  <official_title>Efficacy of Naltrexone in Women's Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed study is to conduct a randomized, double-blind clinical trial to
      compare adjunct treatment with 50 mg oral naltrexone vs. placebo in conjunction with standard
      smoking cessation treatment with nicotine patch and counseling.

      Hypotheses:

        1. Naltrexone will improve smoking cessation quit rates, as measured at the end of active
           treatment (3 months) and during long term follow up (1 year).

        2. Weight and smoking-related variables (i.e., less weight gain, as well as reduced craving
           and withdrawal) will be important factors by which naltrexone improves smoking cessation
           outcome.

        3. These effects are predicted to be stronger in women compared to men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although women may be particularly susceptible to the damaging effects of chronic cigarette
      smoking, evidence indicates that they may have more difficulty in maintaining smoking
      cessation than men. Given women's reduced response to nicotine replacement and other
      traditional treatments to habitual cigarette smoking, more targeted pharmacotherapy and
      intervention strategies may be necessary to improve their quit rates. Preliminary data by our
      group and others indicate that the opioid antagonist naltrexone may be an effective
      adjunctive pharmacotherapy approach for female smokers. The purpose of the proposed study is
      to conduct a randomized clinical trial to compare adjunct treatment with 50 mg oral
      naltrexone vs. placebo in conjunction with standard smoking cessation treatment with nicotine
      patch and counseling. Participants (N=324) will be randomized to receive either naltrexone or
      placebo starting one week prior to the quit date (25 mg for three days; 50 mg thereafter) and
      continue for 12 weeks after the quit date. The effects of naltrexone will be evaluated during
      the pre-quit date period, initial smoking cessation, relapse prevention, and at one year
      follow-up. It is hypothesized that sex will moderate the effects of naltrexone on outcome,
      with naltrexone improving prolonged abstinence quit rates in women but not in men. The
      secondary goal will be to elucidate the mechanism underlying women's treatment response to
      naltrexone. Weight (relative weight gain and weight concerns) and smoking-related variables
      (reduced cigarette pleasure, taste, craving and relief of negative withdrawal affect) may be
      important factors by which naltrexone improves quit rates in women. Medication compliance,
      psychosocial stress and levels of naltrexone's metabolite, 6-B-naltrexol, will also be
      examined. In sum, the proposed clinical trial will provide a comprehensive study of sex
      differences in response to adjunct treatment with naltrexone for smoking cessation. Given the
      public health concerns and significant health consequences of women's continued high rates of
      smoking, the proposed study may provide important information on a novel treatment strategy
      targeting the endogenous opioid system to selectively aid in women's smoking cessation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolonged Smoking Abstinence: 4 Weeks Post Quit-Date</measure>
    <time_frame>4 Weeks Following Smoking Quit Date (Study week 7)</time_frame>
    <description>Prolonged Abstinence at 4 weeks post quit date (Study Week 7). Prolonged Abstinence defined as not smoking (even a puff of a cigarette) at any point during the previous time frame, allowing for a 1-week grace period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prolonged Smoking Abstinence: 12 Weeks Post Quit-Date</measure>
    <time_frame>12 Weeks Following Smoking Quit Date (Study week 15)</time_frame>
    <description>Prolonged Abstinence at 12 weeks post quit date (Study Week 15). Prolonged Abstinence defined as not smoking (even a puff of a cigarette) at any point during the previous time frame, allowing for a 1-week grace period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7-Day Point Prevalence Smoking Abstinence: 4 Weeks Post Quit-Date</measure>
    <time_frame>4 Weeks Following Smoking Quit Date (Study week 7)</time_frame>
    <description>7-Day Point Prevalence smoking abstinence at 4 weeks post quit date (Study Week 7). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7-Day Point Prevalence Smoking Abstinence: 12 Weeks Post Quit-Date</measure>
    <time_frame>12 Weeks Following Smoking Quit Date (Study week 15)</time_frame>
    <description>7-Day Point Prevalence smoking abstinence at 12 weeks post quit date (Study Week 15). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7-Day Point Prevalence Smoking Abstinence: 26 Weeks Post Quit-Date</measure>
    <time_frame>26 Weeks Following Smoking Quit Date (Study week 29)</time_frame>
    <description>7-Day Point Prevalence smoking abstinence at 29 weeks post quit date (Study Week 29). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7-Day Point Prevalence Smoking Abstinence: 52 Weeks Post Quit-Date</measure>
    <time_frame>52 Weeks Following Smoking Quit Date (Study week 55)</time_frame>
    <description>7-Day Point Prevalence smoking abstinence at 52 weeks post quit date (Study Week 55). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Change at End of Treatment (Smoking Abstinent Only)</measure>
    <time_frame>Weight change at 12 weeks post smoking quit date (study week 15)</time_frame>
    <description>Weight change in lbs at 12 weeks post smoking quit date (study week 15) for only those reporting continued smoking abstinence at the end of treatment. All data are Mean(SEM) and represent positive change, unless otherwise noted. Smoking abstinent for this measure defined as no smoking even 1 puff of a cigarette since the smoking quit date (study week 3), allowing for a 1-week grace period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Change at End of Treatment (Regardless of Quit Status)</measure>
    <time_frame>Weight change at 12 weeks post quit date (study week 15) from smoking quit date</time_frame>
    <description>Weight change at 12 weeks post quit date (study week 15) for the whole sample regardless of quit status. All data is Mean(SEM) and represents a positive change unless otherwise noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Antagonist Reported Side Effects: 1-Week Post Quit Date</measure>
    <time_frame>1-Week Post Quit Date (Study Week 4)</time_frame>
    <description>Participants reporting side effects during the previous week by pill type and sex, 1-week following quit date (Study week 4). Participants rated side effects experienced by None, Mild, or Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Antagonist Reported Side Effects: 4-Weeks Post Quit Date</measure>
    <time_frame>4-Weeks Post Quit Date (Study Week 7)</time_frame>
    <description>Participants reporting side effects during the previous week by pill type and sex, 4-weeks following quit date (Study week 7). Participants rated side effects experienced by None, Mild, or Severe.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Smoking</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Male Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Naltrexone tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Females receiving either naltrexone (50 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Males receiving Placebo (sugar pill)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Females receiving placebo (sugar pill)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone (drug)</intervention_name>
    <description>50 mg q.d. for 13 weeks</description>
    <arm_group_label>Male Naltrexone</arm_group_label>
    <arm_group_label>Female Naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Naltrexone)</intervention_name>
    <description>Sugar pill manufactured to mimic Naltrexone tablet</description>
    <arm_group_label>Male Placebo</arm_group_label>
    <arm_group_label>Female Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-65, male or female

          2. Cigarette smoker of at least 15 but no more than 40 cigarettes daily for at least two
             years

          3. Current diagnosis of DSM-IV Nicotine Dependence, based on SCID interview

          4. Relatively healthy, with no medical or psychiatric conditions that would adversely
             interact with study parameters (see exclusion criteria for specific details)

          5. Desire to quit smoking (self-report rating of interest in quitting at least a 7 on a
             10-point scale)

          6. NicometerÂ® cotinine level at baseline at least a 5 on a 6-point scale

          7. Reports not quitting smoking in the past three months for more than one week duration

          8. Agrees to attend behavioral counseling sessions and complete study measures

          9. Has stable residence and telephone and can provide the name of an outside household
             collateral family member or close friend

        Exclusion Criteria:

          1. Substance Dependence in the last one year (other than DSM-IV Nicotine Dependence) or
             any history of Opioid Dependence (lifetime)

          2. Major psychiatric disorder in the last one year, including Axis I disorders or any
             history of moderate/severe Axis II Disorder, Bipolar Disorder or Psychotic Disorder,
             based on SCID interview and standard cut-off thresholds on screening questionnaires

          3. Past or current medical disorders (cardiovascular, hepatic, neurological, endocrine,
             etc.) which may adversely interact with study measures

          4. Clinically significant lab test abnormalities, positive urine toxicology, or positive
             pregnancy test

          5. Currently pregnant, plans to become pregnant, or lack of effective birth control over
             next three months, and/or currently lactating, or plans for breastfeeding over next
             three months

          6. History of adverse reaction to opioid antagonist or nicotine replacement treatment

          7. Use of any medication that may adversely interact with study measures
             (antidepressants, phenothiazines, benzodiazepines, etc.); recent or regular use of an
             opioid medication

          8. Unwillingness to attend smoking cessation treatment sessions, take the nicotine patch,
             or be randomized into medication or placebo conditions, or be available for follow-up
             assessments

          9. Unwillingness to agree to DNA analysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea C King, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Chicago, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago, Department of Psychiatry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://stopsmoking.uchicago.edu</url>
    <description>Main Study Website</description>
  </link>
  <reference>
    <citation>King AC, Meyer PJ. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav. 2000 Jul;66(3):563-72.</citation>
    <PMID>10899371</PMID>
  </reference>
  <reference>
    <citation>King AC. Role of naltrexone in initial smoking cessation: preliminary findings. Alcohol Clin Exp Res. 2002 Dec;26(12):1942-4.</citation>
    <PMID>12500129</PMID>
  </reference>
  <reference>
    <citation>Epstein AM, King AC. Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav. 2004 Jan;77(1):29-37.</citation>
    <PMID>14724039</PMID>
  </reference>
  <reference>
    <citation>King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res. 2006 Oct;8(5):671-82.</citation>
    <PMID>17008194</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2005</study_first_submitted>
  <study_first_submitted_qc>December 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2005</study_first_posted>
  <results_first_submitted>December 19, 2012</results_first_submitted>
  <results_first_submitted_qc>March 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2013</results_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chicago</investigator_affiliation>
    <investigator_full_name>Andrea King</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Smoking Cessation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment for this study lasted from August 2006-March 2009 with study visits taking place in 3 sites (The University of Chicago, Howard Brown Health Clinic, and the Respiratory Health Association). Follow-up interviews for the study concluded in April 2010.</recruitment_details>
      <pre_assignment_details>N=707 screened for participation (320 met exclusion criteria, 54/387 who passed chose not to participate)
333 participants were randomized into the trial</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone - MALE</title>
          <description>Males receiving naltrexone as part of the trial</description>
        </group>
        <group group_id="P2">
          <title>Placebo - MALE</title>
          <description>Males receiving placebo as part of the trial</description>
        </group>
        <group group_id="P3">
          <title>Naltrexone - FEMALE</title>
          <description>Females receiving naltrexone as part of the trial</description>
        </group>
        <group group_id="P4">
          <title>Placebo - FEMALE</title>
          <description>Females receiving placebo as part of the trial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="76">n=4 did not start treatment (3 lost interest, 1 unknown)</participants>
                <participants group_id="P2" count="71">n=6 did not start treatment (1 diff treat. desired, 3 lost interest, 1 began psych meds, 1 unknown)</participants>
                <participants group_id="P3" count="85">n=3 did not start treatment (2 lost interest, 1 unknown)</participants>
                <participants group_id="P4" count="83">n=5 did not start treatment (2 health problems, 1 wanted diff. treatment method, 2 lost interest)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58">Discontinued: 1 smoking related, 1 reaction to tablet, 6 time commitment, 2 other, 8 unspecified</participants>
                <participants group_id="P2" count="51">Discontinued: 5 smoking related, 3 reaction to tablet, 2 time commitment, 1 other, 9 unspecified</participants>
                <participants group_id="P3" count="65">Discontinued: 5 smoking related, 4 reaction to tablet, 4 time commitment, 3 other, 4 unspecified</participants>
                <participants group_id="P4" count="64">Discontinued: 9 smoking related, 2 reaction to tablet, 4 time commitment, 1 other, 3 unspecified</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost Interest</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown/Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unpleasant Reaction To Tablet</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Time Commitment, Scheduling, or Travel</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone - MALE</title>
          <description>Males receiving naltrexone as part of the trial</description>
        </group>
        <group group_id="B2">
          <title>Placebo - MALE</title>
          <description>Males receiving placebo as part of the trial</description>
        </group>
        <group group_id="B3">
          <title>Naltrexone - FEMALE</title>
          <description>Females receiving naltrexone as part of the trial</description>
        </group>
        <group group_id="B4">
          <title>Placebo - FEMALE</title>
          <description>Females receiving placebo as part of the trial</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="88"/>
            <count group_id="B4" value="88"/>
            <count group_id="B5" value="333"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.45" spread="10.97"/>
                    <measurement group_id="B2" value="40.21" spread="10.98"/>
                    <measurement group_id="B3" value="44.34" spread="11.49"/>
                    <measurement group_id="B4" value="44.95" spread="10.45"/>
                    <measurement group_id="B5" value="42.13" spread="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prolonged Smoking Abstinence: 4 Weeks Post Quit-Date</title>
        <description>Prolonged Abstinence at 4 weeks post quit date (Study Week 7). Prolonged Abstinence defined as not smoking (even a puff of a cigarette) at any point during the previous time frame, allowing for a 1-week grace period.</description>
        <time_frame>4 Weeks Following Smoking Quit Date (Study week 7)</time_frame>
        <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - MALE</title>
            <description>Males receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo - MALE</title>
            <description>Males receiving placebo as part of the trial</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone - FEMALE</title>
            <description>Females receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FEMALE</title>
            <description>Females receiving placebo as part of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Smoking Abstinence: 4 Weeks Post Quit-Date</title>
          <description>Prolonged Abstinence at 4 weeks post quit date (Study Week 7). Prolonged Abstinence defined as not smoking (even a puff of a cigarette) at any point during the previous time frame, allowing for a 1-week grace period.</description>
          <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Change at End of Treatment (Smoking Abstinent Only)</title>
        <description>Weight change in lbs at 12 weeks post smoking quit date (study week 15) for only those reporting continued smoking abstinence at the end of treatment. All data are Mean(SEM) and represent positive change, unless otherwise noted. Smoking abstinent for this measure defined as no smoking even 1 puff of a cigarette since the smoking quit date (study week 3), allowing for a 1-week grace period.</description>
        <time_frame>Weight change at 12 weeks post smoking quit date (study week 15)</time_frame>
        <population>All participants completing through smoking quit date (study week 3) and who were smoking abstinent at end of treatment (study week 15)</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - MALE</title>
            <description>Males receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo - MALE</title>
            <description>Males receiving placebo as part of the trial</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone - FEMALE</title>
            <description>Females receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FEMALE</title>
            <description>Females receiving placebo as part of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Change at End of Treatment (Smoking Abstinent Only)</title>
          <description>Weight change in lbs at 12 weeks post smoking quit date (study week 15) for only those reporting continued smoking abstinence at the end of treatment. All data are Mean(SEM) and represent positive change, unless otherwise noted. Smoking abstinent for this measure defined as no smoking even 1 puff of a cigarette since the smoking quit date (study week 3), allowing for a 1-week grace period.</description>
          <population>All participants completing through smoking quit date (study week 3) and who were smoking abstinent at end of treatment (study week 15)</population>
          <units>Pounds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="0.78"/>
                    <measurement group_id="O2" value="5.58" spread="0.78"/>
                    <measurement group_id="O3" value="2.26" spread="0.68"/>
                    <measurement group_id="O4" value="5.08" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prolonged Smoking Abstinence: 12 Weeks Post Quit-Date</title>
        <description>Prolonged Abstinence at 12 weeks post quit date (Study Week 15). Prolonged Abstinence defined as not smoking (even a puff of a cigarette) at any point during the previous time frame, allowing for a 1-week grace period.</description>
        <time_frame>12 Weeks Following Smoking Quit Date (Study week 15)</time_frame>
        <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - MALE</title>
            <description>Males receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo - MALE</title>
            <description>Males receiving placebo as part of the trial</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone - FEMALE</title>
            <description>Females receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FEMALE</title>
            <description>Females receiving placebo as part of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Smoking Abstinence: 12 Weeks Post Quit-Date</title>
          <description>Prolonged Abstinence at 12 weeks post quit date (Study Week 15). Prolonged Abstinence defined as not smoking (even a puff of a cigarette) at any point during the previous time frame, allowing for a 1-week grace period.</description>
          <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>7-Day Point Prevalence Smoking Abstinence: 4 Weeks Post Quit-Date</title>
        <description>7-Day Point Prevalence smoking abstinence at 4 weeks post quit date (Study Week 7). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
        <time_frame>4 Weeks Following Smoking Quit Date (Study week 7)</time_frame>
        <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - MALE</title>
            <description>Males receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo - MALE</title>
            <description>Males receiving placebo as part of the trial</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone - FEMALE</title>
            <description>Females receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FEMALE</title>
            <description>Females receiving placebo as part of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>7-Day Point Prevalence Smoking Abstinence: 4 Weeks Post Quit-Date</title>
          <description>7-Day Point Prevalence smoking abstinence at 4 weeks post quit date (Study Week 7). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
          <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Change at End of Treatment (Regardless of Quit Status)</title>
        <description>Weight change at 12 weeks post quit date (study week 15) for the whole sample regardless of quit status. All data is Mean(SEM) and represents a positive change unless otherwise noted.</description>
        <time_frame>Weight change at 12 weeks post quit date (study week 15) from smoking quit date</time_frame>
        <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome, regardless of their abstinence status at 12 weeks post quit date (study week 15)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants receiving Placebo as part of the trial</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone</title>
            <description>Participants receiving Naltrexone as part of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Change at End of Treatment (Regardless of Quit Status)</title>
          <description>Weight change at 12 weeks post quit date (study week 15) for the whole sample regardless of quit status. All data is Mean(SEM) and represents a positive change unless otherwise noted.</description>
          <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome, regardless of their abstinence status at 12 weeks post quit date (study week 15)</population>
          <units>Pounds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="0.52"/>
                    <measurement group_id="O2" value="3.42" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>7-Day Point Prevalence Smoking Abstinence: 12 Weeks Post Quit-Date</title>
        <description>7-Day Point Prevalence smoking abstinence at 12 weeks post quit date (Study Week 15). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
        <time_frame>12 Weeks Following Smoking Quit Date (Study week 15)</time_frame>
        <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - MALE</title>
            <description>Males receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo - MALE</title>
            <description>Males receiving placebo as part of the trial</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone - FEMALE</title>
            <description>Females receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FEMALE</title>
            <description>Females receiving placebo as part of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>7-Day Point Prevalence Smoking Abstinence: 12 Weeks Post Quit-Date</title>
          <description>7-Day Point Prevalence smoking abstinence at 12 weeks post quit date (Study Week 15). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
          <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>7-Day Point Prevalence Smoking Abstinence: 26 Weeks Post Quit-Date</title>
        <description>7-Day Point Prevalence smoking abstinence at 29 weeks post quit date (Study Week 29). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
        <time_frame>26 Weeks Following Smoking Quit Date (Study week 29)</time_frame>
        <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - MALE</title>
            <description>Males receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo - MALE</title>
            <description>Males receiving placebo as part of the trial</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone - FEMALE</title>
            <description>Females receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FEMALE</title>
            <description>Females receiving placebo as part of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>7-Day Point Prevalence Smoking Abstinence: 26 Weeks Post Quit-Date</title>
          <description>7-Day Point Prevalence smoking abstinence at 29 weeks post quit date (Study Week 29). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
          <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>7-Day Point Prevalence Smoking Abstinence: 52 Weeks Post Quit-Date</title>
        <description>7-Day Point Prevalence smoking abstinence at 52 weeks post quit date (Study Week 55). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
        <time_frame>52 Weeks Following Smoking Quit Date (Study week 55)</time_frame>
        <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - MALE</title>
            <description>Males receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo - MALE</title>
            <description>Males receiving placebo as part of the trial</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone - FEMALE</title>
            <description>Females receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FEMALE</title>
            <description>Females receiving placebo as part of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>7-Day Point Prevalence Smoking Abstinence: 52 Weeks Post Quit-Date</title>
          <description>7-Day Point Prevalence smoking abstinence at 52 weeks post quit date (Study Week 55). 7-Day Point Prevalence abstinence defined as not smoking (even a puff) for seven days in a row or on one day in each of two consecutive weeks during the previous time frame.</description>
          <population>All participants who received study treatment by participating through smoking quit date (Study Week 3)were analyzed for this outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Antagonist Reported Side Effects: 1-Week Post Quit Date</title>
        <description>Participants reporting side effects during the previous week by pill type and sex, 1-week following quit date (Study week 4). Participants rated side effects experienced by None, Mild, or Severe.</description>
        <time_frame>1-Week Post Quit Date (Study Week 4)</time_frame>
        <population>All participants who received study treatment by participating through smoking quit date (Study Week 3) were analyzed for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - MALE</title>
            <description>Males receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo - MALE</title>
            <description>Males receiving placebo as part of the trial</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone - FEMALE</title>
            <description>Females receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FEMALE</title>
            <description>Females receiving placebo as part of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Antagonist Reported Side Effects: 1-Week Post Quit Date</title>
          <description>Participants reporting side effects during the previous week by pill type and sex, 1-week following quit date (Study week 4). Participants rated side effects experienced by None, Mild, or Severe.</description>
          <population>All participants who received study treatment by participating through smoking quit date (Study Week 3) were analyzed for this outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache- &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Light Headed/Dizzy - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Light Headed/Dizzy - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flushed/Warm - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flushed/Warm - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Agitation - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Agitation - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Sexual Desire - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Sexual Desire - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint or Muscle Pain - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint or Muscle Pain - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Antagonist Reported Side Effects: 4-Weeks Post Quit Date</title>
        <description>Participants reporting side effects during the previous week by pill type and sex, 4-weeks following quit date (Study week 7). Participants rated side effects experienced by None, Mild, or Severe.</description>
        <time_frame>4-Weeks Post Quit Date (Study Week 7)</time_frame>
        <population>All participants who received study treatment by participating through smoking quit date (Study Week 3) were analyzed for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone - MALE</title>
            <description>Males receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo - MALE</title>
            <description>Males receiving placebo as part of the trial</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone - FEMALE</title>
            <description>Females receiving naltrexone as part of the trial</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FEMALE</title>
            <description>Females receiving placebo as part of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Antagonist Reported Side Effects: 4-Weeks Post Quit Date</title>
          <description>Participants reporting side effects during the previous week by pill type and sex, 4-weeks following quit date (Study week 7). Participants rated side effects experienced by None, Mild, or Severe.</description>
          <population>All participants who received study treatment by participating through smoking quit date (Study Week 3) were analyzed for this outcome.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache- &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Light Headed/Dizzy - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Light Headed/Dizzy - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flushed/Warm - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flushed/Warm - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Agitation - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Agitation - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Sexual Desire - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Sexual Desire - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint or Muscle Pain - &quot;Mild&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint or Muscle Pain - &quot;Severe&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Number of participant at risk represent those assigned to either Naltrexone or Placebo condition (i.e. receiving treatment) - Placebo: n=154, Naltrexone: n=161</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants receiving Placebo as part of the trial</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone</title>
          <description>Participants receiving Naltrexone as part of the trial</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Motor Vehicle Collision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Brain Mass</sub_title>
                <description>Participant reported this during time of study; however, diagnosed as having developed prior to study participation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lung Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation Remitting in 2 Days with Recurrence</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Lightheaded or dizzy</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Flushed or warm</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Agitation or anxiety</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Increased Sexual Desire</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrea King</name_or_title>
      <organization>University of Chicago</organization>
      <phone>7737026181</phone>
      <email>aking@bsdad.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

